French Lisa 4
4 · Keenova Therapeutics plc · Filed Jan 5, 2026
Insider Transaction Report
Form 4
French Lisa
EVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2026-01-01+6,576→ 10,376 total - Tax Payment
Ordinary Shares
2026-01-01−1,986→ 8,390 total - Exercise/Conversion
Restricted Stock Units
2026-01-01−6,576→ 46,031 total→ Ordinary Shares (6,576 underlying)
Footnotes (4)
- [F1]Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
- [F2]The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
- [F3]On February 2, 2024, the Reporting Person was granted 16,413 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.
- [F4]Reflects that the Reporting Person received 8,836 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.